MDGL
NASDAQ
US
Madrigal Pharmaceuticals, Inc. - Common Stock
$546,89
▲ +$17,05
(+3,22%)
Vol. 345K
5
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$13.2B
ROE
-41,5%
Margine
-39,0%
D/E
54,30
Beta
-1,07
52W
$265–$615
Consenso Wall Street
23 analisti · Apr 20265
Acquisto forte
15
Compra
3
Mantieni
0
Vendi
0
Vendita forte
87,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
MRNA
Moderna Inc
$11.5B
INCY
Incyte Corp
P/E 16,3
$19.4B
SMMT
Summit Therapeutics Inc
$13.0B
BBIO
BridgeBio Pharma Inc
$14.7B
NBIX
Neurocrine Biosciences Inc
P/E 33,0
$14.1B
IONS
Ionis Pharmaceuticals Inc
$12.8B
EXEL
Exelixis Inc
P/E 17,3
$11.8B
BMRN
BioMarin Pharmaceutical Inc
P/E 21,9
$11.4B
PRAX
Praxis Precision Medicines Inc
$7.4B
ARWR
Arrowhead Pharmaceuticals Inc
$9.0B
Utili
Tasso di battuta: 50,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-0,69 | $-2,57 | $-1,88 |
| Set 2025 | $-2,12 | $-4,96 | $-2,84 |
| Giu 2025 | $-3,71 | $-1,90 | +$1,81 |
| Mar 2025 | $-3,84 | $-3,32 | +$0,52 |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -38.4% | -38.4% | -38.4% | -38.4% | -41.5% | -41.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -19.9% | -54.7% | -54.7% | -54.7% | -39.0% | -39.0% |
| Gross Margin | 95.7% | 96.3% | 96.3% | 96.3% | 95.2% | 95.2% |
| D/E Ratio | 17.01 | 17.01 | 17.01 | 17.01 | 54.30 | 54.30 |
| Current Ratio | 5.11 | 5.11 | 5.11 | 5.11 | 3.44 | 3.44 |
Rapporti chiave
ROA (TTM)
-26,2%
P/S (TTM)
17,86
P/B
8,9
EPS (TTM)
$-13,01
CF/Share
$-19,21
52W High
$615,00
52W Low
$265,00
$265,00
Intervallo 52 settimane
$615,00
Як MDGL виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка MDGL vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
17,9
▲
39%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
8,9
▲
263%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість MDGL vs аналоги Biotechnology
ROE
-41,5%
▲
38%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Sotto media
Net margin
-39,0%
▲
86%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
95,3%
▲
21%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-26,2%
▲
44%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя MDGL vs аналоги Biotechnology
D/E ratio
54,3
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
3,4
▼
23%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
-1,1
▼
211%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів MDGL
MDGL
Mediana peer
Industria
MDGL прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio